【摘要】 目的评价苯那普利对糖尿病肾病(DN)的临床疗效,并探讨相应作用机制。方法采用随机对照研究,观察苯那普利治疗前后DN患者24h平均尿微量白蛋白排泄量以及尿转化生长因子β1(TGF-β1)、层黏连蛋白(LAM)和Ⅳ型胶原(CⅣ)的变化。结果苯那普利治疗6月后,患者24h尿微量白蛋白平均排泄量为(0·044±0·034)g,尿TGF-β1为(1·48±0·59)μg/L,LAM为(22·74±23·26)μg/L量,CⅣ浓度为(13·47±10·94)μg/L量,均较治疗前有显著降低(P<0·05),而对照组则较基线值明显升高(P<0·05)。结论苯那普利可以有效降低血压、抑制肾脏TGF-β1、LAM及CⅣ的表达、显著减少DN患者尿蛋白的排出,从而发挥其肾脏保护作用。更多还原

【Abstract】 Objective To investigate the effect of benazepril on the patients with diabetic nephropathy （DN）. Methods Patients with DN were randomly assigned into control group and benazepril-treated group. Urinary microalbuminuria, TGF-β₁, type Ⅳ collagen and laminin were detected at baseline and six months later. Results The level of urinary microalbuminuria,TGF-β₁,type Ⅳ collagen and laminin was 0.044±0.034 g, 1.48±0.59 μg/L, 13.47±10.94 μg/L, and 22.74±23.26 μg/L in benazepril treated group,respectively. Conclusions Benazepril can decrease blood pressure dramatically and prevent the development of DN through inhibiting the secretion of TGF-β₁, type Ⅳ collagen and laminin.更多还原